Skip to main content
. 2023 May 10;45(4):922–928. doi: 10.1007/s11096-023-01587-9

Table 1.

Summary of all individual case safety reports (ICSRs) related to (suspect or interacting) oxytocin and carbetocin within VigiBase, the World Health Organization’s database for ICSRs

Oxytocin (%) Carbetocin (%)
Total ICSR 11,258 (100) 374 (100)
Total reactions 21,274 (100) 700 (100)
Patients
 Age [y]
  Mean (SD) 29.4 (8.4) 31.2 (7.5)
  Under 1 177 (1.6) 5 (1.3)
  1–14 24 (0.2) 1 (0.3)
  15–24 1 774 (15.8) 29 (7.8)
  25–34 4 933 (43.8) 185 (49.5)
  35–44 1 622 (14.4) 96 (25.7)
  45–54 258 (2.3) 2 (0.5)
  Over 55 47 (0.4) 1 (0.3)
  Not reported 2 433 (21.5) 55 (14.7)
 Sex
  Female 10,402 (92.4) 368 (98.4)
  Not reported 656 (5.8) 4 (1.1)
Reports
 Additional drugs
  Mean (SD) 0.9 (1.9) 1.3 (2.5)
  Range 0–30 0–18
 Additional uterotonics*
  Mean (SD) 0.1 (0.4) 0.2 (0.6)
  Range 0–7 0–4
 Most common concomitant drugs
  Glucose 945 (8.4) 9 (2.4)
  Sodium chloride 941 (8.4) 23 (6.1)
  Dinoprostone 524 (4.7) 1 (0.3)
  Misoprostol 520 (4.6) 8 (2.1)
  Bupivacaine 332 (2.9) 10 (2.7)
  Fentanyl 287 (2.5) 16 (4.3)
  Ringer’s solution 193 (1.7) 11 (2.9)
  Cefazolin 161 (1.4) 19 (5.1)
  Paracetamol 109 (1.0) 7 (1.9)
  Propofol 105 (0.9) 2 (0.5)
  Carboprost 76 (0.7) 20 (5.3)
  Sufentanil 72 (0.6) 16 (4.3)
  Ephedrine 71 (0.6) 15 (4.0)
  Oxytocin n.a 60 (16.0)
  Carbetocin 31 (0.3) n.a
  Not coded 458 (4.1) 19 (5.1)
 Origin of report
  Africa 159 (1.4) 14 (3.7)
  America 1 446 (12.8) 31 (8.3)
  Asia 6 929 (61.5) 219 (58.6)
  Europe 2 292 (20.4) 90 (24.4)
  Oceania 417 (3.7) 20 (5.3)
  Not reported 15 (0.1) 0 (0.0)
 Serious
  Yes 3 412 (30.3) 145 (38.8)
  No 6 426 (57.1) 184 (49.2)
  Not reported 1 420 (12.6) 45 (12.0)
 Fatal
  Yes 164 (1.5) 3 (0.8)

*Uterotonics included: “Methylergometrine”, “Ergot alkaloids”, “Ergometrine”, “Dinoprostone”, “Gemeprost”, “Carboprost”, “Sulprostone”, “Misoprostol”